Equities

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA

Actions
  • Price (CHF)1.45
  • Today's Change0.00 / 0.00%
  • Shares traded2.22k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Feb 24 2022 16:34 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

  • Revenue in CHF (TTM)5.59m
  • Net income in CHF-14.46m
  • Incorporated2002
  • Employees25.00
  • Location
    Newron Pharmaceuticals SpAvia Ludovico Ariosto 21BRESSO 20091ItalyITA
  • Phone+39 26103461
  • Fax+39 261034654
  • Websitehttps://www.newron.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.